This phase II study was designed to evaluate the activity and safety of a combination of irinotecan, docetaxel and oxaliplatin in metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

• 本文进行联合依立替康、紫杉醇和奥沙利铂治疗转移性胃腺癌和胃及食管连接部腺癌的临床II期实验来评价疗效和安全性。